Ingevity (NYSE:NGVT) Issues Earnings Results, Misses Estimates By $0.16 EPS

Ingevity (NYSE:NGVT) released its earnings results on Wednesday. The company reported $0.58 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.74 by ($0.16), Zacks reports. The firm had revenue of $255.10 million for the quarter, compared to the consensus estimate of $257.27 million. Ingevity had a positive return on equity of 103.69% and a negative net margin of 5.14%. Ingevity updated its FY 2026 guidance to 4.800-5.20 EPS.

Ingevity Stock Performance

NGVT stock traded down $1.25 during trading hours on Wednesday, reaching $69.87. The stock had a trading volume of 395,177 shares, compared to its average volume of 302,218. The stock has a 50-day simple moving average of $66.52 and a 200 day simple moving average of $58.83. Ingevity has a fifty-two week low of $28.49 and a fifty-two week high of $77.46. The stock has a market capitalization of $2.51 billion, a PE ratio of -38.39 and a beta of 1.34. The company has a debt-to-equity ratio of 8.39, a current ratio of 1.27 and a quick ratio of 0.80.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on NGVT. BMO Capital Markets increased their price objective on Ingevity from $64.00 to $70.00 and gave the stock an “outperform” rating in a report on Wednesday, December 10th. Wall Street Zen downgraded Ingevity from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ingevity in a report on Thursday, January 22nd. Zacks Research raised shares of Ingevity to a “hold” rating in a research report on Tuesday, December 16th. Finally, Wells Fargo & Company raised their target price on shares of Ingevity from $60.00 to $65.00 and gave the company an “equal weight” rating in a research report on Wednesday, January 28th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $67.50.

Institutional Investors Weigh In On Ingevity

Several hedge funds have recently bought and sold shares of NGVT. Global Retirement Partners LLC acquired a new position in shares of Ingevity in the fourth quarter valued at about $27,000. Meeder Asset Management Inc. bought a new position in shares of Ingevity during the fourth quarter worth approximately $33,000. Geneos Wealth Management Inc. increased its holdings in shares of Ingevity by 85.8% during the second quarter. Geneos Wealth Management Inc. now owns 838 shares of the company’s stock worth $36,000 after purchasing an additional 387 shares during the period. Headlands Technologies LLC acquired a new stake in shares of Ingevity in the second quarter valued at approximately $46,000. Finally, Kestra Advisory Services LLC bought a new stake in shares of Ingevity in the fourth quarter valued at approximately $47,000. 91.59% of the stock is currently owned by institutional investors and hedge funds.

Ingevity Company Profile

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.